289503-26-0

Upstream product

• 189265-99-4 6-bromo-1-(4-methylphenylsulfonyl)-1H-indole 
• 52415-29-9 6-bromo-1H-indole 
• 98-59-9 p-toluenesulfonyl chloride 
• 289503-25-9 N-tosyl-3,6-dibromoindole 

Downstream Products

• 289503-27-1 2-amino-4-(N-tosyl-6'-bromo-3'-indolyl)pyrimidine 
• 476623-17-3 5-bromo-3-methoxy-2-(N-tosyl-6-bromoindol-3-yl)pyrazine 
• 476622-84-1 7-Benzyloxy-3-{5-[6-bromo-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-6-methoxy-pyrazin-2-yl}-4-[2-(tert-butyl-dimethyl-silanyloxy)-1-methyl-ethyl]-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indole 
• 476623-35-5 1-amino-3-[7-benzyloxy-3-{5-[6-bromo-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-6-methoxy-pyrazin-2-yl}-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indol-4-yl]-butan-2-one 
• 476623-26-4 3-[7-benzyloxy-3-{5-[6-bromo-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-6-methoxy-pyrazin-2-yl}-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indol-4-yl]-1-nitro-butan-2-one 
• 476623-19-5 3-[7-benzyloxy-3-{5-[6-bromo-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-6-methoxy-pyrazin-2-yl}-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indol-4-yl]-1-bromo-butan-2-one 
• 476623-34-4 3-[7-benzyloxy-3-{5-[6-bromo-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-6-methoxy-pyrazin-2-yl}-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indol-4-yl]-1-diazo-butan-2-one 
• 476623-18-4 2-[7-benzyloxy-3-{5-[6-bromo-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-6-methoxy-pyrazin-2-yl}-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indol-4-yl]-propionic acid 
• 476623-24-2 2-[7-benzyloxy-3-{5-[6-bromo-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-6-methoxy-pyrazin-2-yl}-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indol-4-yl]-propionaldehyde 
• 476623-27-5 3-{7-benzyloxy-3-[5-(6-bromo-1H-indol-3-yl)-6-methoxy-pyrazin-2-yl]-1H-indol-4-yl}-1-nitro-butan-2-one 
• 1026440-93-6 6-Bromo-3-{3-methoxy-5-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-indol-3-yl]-pyrazin-2-yl}-1-(toluene-4-sulfonyl)-1H-indole 

Relevant academic research and scientific papers

The first total synthesis of dragmacidin D

The first total synthesis of the biologically significant bis-indole alkaloid dragmacidin D (5) has been achieved. Thermal and electronic modulation provides the key for a series of palladium-catalyzed Suzuki cross-coupling reactions that furnished the core structure of the complex guanidine- and aminoimidazole-containing dragmacidins. Following this crucial sequence, a succession of meticulously controlled final events was developed leading to the completion of the natural product.

Synthesis of novel analogues of marine indole alkaloids: Mono(indolyl)-4-trifluoromethylpyridines and bis(indolyl)-4-trifluoromethylpyridines as potential anticancer agents

Mono(indolyl)-4-trifluoromethylpyridines and bis(indolyl)-4-trifluoromethylpyridines were synthesized using Suzuki cross-coupling reaction between 2-chloro-4-trifluoromethylpyridine 9, 2,6-dichloro-4-trifluoromethylpyridine 6 or 2,6-dichloro-3-cyano-4-tri

Synthesis of indolylpyrimidines via cross-coupling of indolylboronic acid with chloropyrimidines facile synthesis of meridianin D

Palladium catalyzed cross-coupling reaction of 3-indolylboronic acid with 2,4-dichloropyrimidines proceeded regioselectively to yield indolyl-or bis(indolyl)pyrimidines in high yield, depending on the projection of 3indolylboronic acid. The marine indole alkaloid meridianin D and an analogue were synthesised via the palladium catalyzed cross-coupling reaction as a key step.